Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

CL-387785

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

HER-2 L755S	Gastric Cancer	HER-2 L755S	Gastric Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755P	Non Small Cell Lung Cancer	HER-2 L755P	Non Small Cell Lung Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 T798M	Breast Cancer	HER-2 T798M	Breast Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755P	Breast Cancer	HER-2 L755P	Breast Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D
HER-2 L755S	Breast Cancer	HER-2 L755S	Breast Cancer	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D	CL-387785 Sensitive: D – Preclinical CL-387785 Sensitive : D